Lenvatinib Combined with Tislelizumab and TACE Applied As Neoadjuvant Regimen for the Patients of CNLC Stage IB and IIA Hepatocellular Carcinoma with High-risk Recurrence Factors

This study is testing whether giving liver cancer patients three treatments together — lenvatinib (a targeted drug), tislelizumab (an immunotherapy), and TACE (a procedure that delivers chemotherapy directly to the liver tumor and blocks its blood supply) — before surgery can reduce the chances of the cancer coming back after the operation. This is for patients with early to intermediate-stage liver cancer that has features suggesting a higher risk of recurrence. **You may be eligible if:** - You are 18–75 years old - You have been diagnosed with hepatocellular carcinoma (liver cancer) at CNLC stage IB or IIA - Your imaging shows narrow or no surgical margins, and your tumor marker levels (AFP + PIVKA combined) are elevated above a specific threshold - You have not received any prior chemotherapy, immunotherapy, targeted therapy, or other anti-tumor treatment for this liver cancer - Your liver function is well-preserved (Child-Pugh grade A) and you are in good general health **You may NOT be eligible if:** - You have already received systemic anti-cancer treatment for liver cancer - Your liver function is significantly impaired - Your blood counts or organ function do not meet the required levels for surgery and treatment - Your expected survival is less than 16 weeks Talk to your doctor to see if this trial is right for you.